PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Open-label, multicenter, dose titration and four-arm expansion trial to evaluate the safety,
tolerability, immunogenicity, and preliminary efficacy of W_pro1 cancer vaccine (W_pro1)
monotherapy or in combination with cemiplimab in patients with metastatic castration
resistant prostate cancer (mCRPC: Part 1 and Part 2 Arms 1A and 1B) and in patients with
high-risk, localized prostate cancer (LPC).